Provided by Tiger Fintech (Singapore) Pte. Ltd.

HEC CJ PHARM

10.520
+0.6606.69%
Volume:15.61M
Turnover:162.61M
Market Cap:9.26B
PE:18.11
High:10.620
Open:9.860
Low:9.860
Close:9.860
Loading ...

YiChang HEC ChangJiang Pharmaceutical FY Net Income RMB 482.71 Million

THOMSON REUTERS
·
28 Mar

YiChang HEC Gains Approval to Launch Hepatitis C Drug in China

MT Newswires Live
·
28 Mar

BRIEF-Yichang Hec Changjiang Pharmaceutical Says Encofosbuvir Tablets (0.3G) Approved For Launch By NMPA

Reuters
·
27 Mar

YiChang HEC ChangJiang Pharmaceutical - Encofosbuvir Tablets (0.3G) Approved for Launch by Nmpa

THOMSON REUTERS
·
27 Mar

Despite shrinking by HK$405m in the past week, YiChang HEC ChangJiang Pharmaceutical (HKG:1558) shareholders are still up 74% over 3 years

Simply Wall St.
·
03 Mar

Earnings Working Against YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Share Price

Simply Wall St.
·
24 Jan

Has YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Simply Wall St.
·
16 Dec 2024

BRIEF-Yichang HEC Changjiang Pharmaceutical Updates On Filing With Listing Committee

Reuters
·
05 Dec 2024

YiChang HEC ChangJiang Pharmaceutical - Preparation for Filing With Listing Committee Reached an Advanced Stage

THOMSON REUTERS
·
05 Dec 2024

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) delivers shareholders respectable 21% CAGR over 3 years, surging 6.7% in the last week alone

Simply Wall St.
·
18 Nov 2024

Yichang HEC Changjiang Pharmaceutical's Merger Offeror Agreed to License-out Product for $938 Million

MT Newswires Live
·
13 Nov 2024

BRIEF-YiChang HEC Changjiang Pharmaceutical Says Sunshine Lake Pharma To Enter Licensing Agreement

Reuters
·
12 Nov 2024

YiChang HEC ChangJiang Pharmaceutical - Agreement to Develop and Commercialise Apl-18881 (Hec88473), a Fgf21 / Glp-1 Dual Receptor Agonist

THOMSON REUTERS
·
12 Nov 2024

YiChang HEC ChangJiang Pharmaceutical - Sunshine Lake Pharma to Enter Licensing Agreement With Apollo Therapeutics

THOMSON REUTERS
·
12 Nov 2024